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Abstract
Background: Mandatory generic substitution was introduced in Sweden in October 2002 in order
to try to curb escalating pharmaceutical expenditure. The aim of this study was to investigate how
sales patterns for substitutable and non-substitutable pharmaceuticals have developed since the
introduction of mandatory generic substitution; furthermore, to compare sales patterns in different
groups of the population, based on patients' age and gender.
Methods:  Five therapeutic groups comprising both substitutable and non-substitutable
pharmaceuticals were included. The study period was from January 2000 to June 2005. National
sales data were used, covering volumes of dispensed prescription medicines (expressed in defined
daily doses per 1000 inhabitants and day) of each pharmacological substance in the therapeutic
groups for each age and gender group. Sales patterns for substitutable and non-substitutable
pharmaceuticals were compared using a descriptive approach.
Results: In most therapeutic groups there has been an increase in the volumes of substitutable
pharmaceuticals sold since the introduction of the reform, ranging from one third to three times
the initial volume; whereas the volumes of non-substitutable pharmaceuticals have levelled out or
declined. There were few gender differences in sales patterns of substitutable and non-substitutable
drugs. In three therapeutic groups, sales patterns differed across different age groups, and there
was a tendency for volumes of recently introduced non-substitutable pharmaceuticals to be
proportionally higher in the youngest age groups.
Conclusion: Since the introduction of the reform, there has been a proportionally larger increase
in sales of substitutable pharmaceuticals compared with sales of non-substitutable pharmaceuticals.
This indicates that the reform might have contributed to larger sales of less expensive
pharmaceuticals.
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Background
Most countries promote the use of generic drugs, and sev-
eral countries have introduced generic substitution in
order to increase the use of generics [1-6]. Generic substi-
tution has contributed to increased use of generic brands
and to cutting the escalating costs in several countries
[2,3,6]. Some studies have shown that physicians were
reluctant to generic substitution policies [7-9]. There have
been concerns that physicians might perceive it as a threat
to their autonomy, and would thus oppose such policies.
An Australian study reported that physicians more fre-
quently switched therapy for patients using non-substitut-
able drugs than for patients using substitutable drugs, i.e.
pharmaceutical products containing the same active
ingredient with the same strength [5]. The study showed
that therapy was changed in a small proportion of the
patients. The authors of the study noted that possible
explanations for the low frequency of switched therapy
include a clear price signal for the investigated products
contributed to cost-consciousness among prescribers and
patients; and that prescribers were aware of the fact that
problems following changed therapy [5].
In order to increase price competition for medically equiv-
alent products where the patent had expired, Sweden
introduced mandatory generic substitution on 1 October
2002 [10,11]. Prescriptions issued on or after 1 October
2002 were covered by the reform. Prescriptions are valid
for one year in Sweden and thus the reform was fully
implemented a year after the introduction. According to
the Swedish Pharmaceutical Benefits Scheme, PBS,
patients' expenses/co-payments for reimbursed medicines
are accumulated during twelve-month periods, starting on
the day of the first purchase. The patient co-payment cor-
responds to the price of the drugs within the scheme until
the accumulated costs have reached a certain level and
thereafter a decreasing proportion of the price until the
high-cost threshold has been reached. After the high-cost
threshold there is no co-payment for reimbursed pharma-
ceuticals during the rest of the period. The Swedish Medi-
cal Products Agency produces a list of products that are
substitutable, based on the judgement that they are med-
ically equivalent. To be considered as medically equiva-
lent the products must contain the same active
pharmacological substance, of the same strength and in a
comparable package size. According to the law on generic
substitution, pharmacy personnel are obliged to offer the
patient the cheapest available substitutable drug accord-
ing to the MPA's list, unless substitution is restricted [10].
Prescribers can restrict substitution for medical reasons by
marking 'substitution not allowed' on the prescription.
Substitution can also be restricted for other reasons: e.g.
divided doses, such as divided tablets, potential reactions
to non-active ingredients or differences in taste. The phar-
macist makes this decision. If substitution is restricted by
the physician or the pharmacist, the total cost of the pre-
scribed drug is added to the patient's accumulated cost of
drugs purchased within the PBS. The patient can oppose
substitution and retain a more expensive product, given
that he or she pays the price difference between the pre-
scribed and cheapest (reimbursed) product out of pocket.
In this case, the cost of the cheapest product is added to
the patient's accumulated cost of reimbursed drugs if the
patient has not yet reached the high-cost threshold. The
price difference is paid out of pocket, irrespective of the
patient's co-payment status.
The aim of the reform was to reduce costs for off-patent
pharmaceuticals, through increased price competition, as
well as substituting with cheaper equivalents. The intro-
duction of generic substitution was followed by notable
reductions in price for several top-selling products, which
were highlighted in the media and elsewhere. These price
cuts helped to curb the increase of overall pharmaceutical
expenditure in Sweden after the introduction of generic
substitution [12]. Parallel with the introduction of generic
substitution, decentralisation of the responsibility for
costs of pharmaceuticals within the PBS, from the govern-
ment to the county councils, was in progress [13,14]. The
decentralisation was initiated in 1998, continued in 2002
and fully implemented in January 2005. The responsibil-
ity of providing care to citizens lies with the county coun-
cils. County councils have had budget responsibility for
inpatient drugs for many years. The aim of the shift of the
budget responsibility was to integrate outpatient drug
costs in the healthcare budget and make prescribers more
cost-conscious. Today, this budget responsibility is han-
dled at a central level in some county councils, whereas in
some it has been decentralised to the care-unit level. The
process has started a debate regarding cost issues of phar-
maceuticals among physicians.
The introduction of generic substitution implied consid-
erable changes in the prescribing process for prescribers
and patients. The prescribers had to inform the patient
that the pharmacy might substitute the prescribed drug
with a cheaper equivalent and ensure that reports on per-
formed substitutions sent by the pharmacies were docu-
mented in the patient records. The patients faced a new
situation when asked to make decisions about substitu-
tion themselves; previously the prescribers had dealt with
this. Investigating how the sales patterns of prescribed
drugs have developed following the reform indicates
whether the pattern of prescribing has changed since the
reform was introduced. Earlier studies on effects of phar-
maceutical reimbursement policies have shown differ-
ences between overall effects and effects in subgroups of
the population. A previous study reported that although
increased cost-sharing was not associated with negative
effects on health status, decreased use of essential pharma-BMC Health Services Research 2008, 8:50 http://www.biomedcentral.com/1472-6963/8/50
Page 3 of 9
(page number not for citation purposes)
ceuticals or hospital admissions on an overall level a neg-
ative impact on these outcomes was observed for
particularly vulnerable groups such as the elderly and the
poor [15-17]. Investigating how the sales patterns have
developed in different age and gender groups could indi-
cate whether the reform affected these groups differently.
The present study aims to investigate how the sales pat-
terns for substitutable and non-substitutable pharmaceu-
ticals have developed since the introduction of mandatory
generic substitution in Sweden.
More specifically the objectives were:
1) to assess how volumes sold of substitutable pharma-
ceuticals, compared with volumes sold of non-substituta-
ble pharmaceuticals, have changed since the reform was
introduced
2) to investigate whether sales patterns vary between dif-
ferent groups of the population based on patients' age and
gender
Methods
Five therapeutic groups were selected for case studies.
Selection criteria were that the therapeutic groups should
encompass both substitutable and non-substitutable
pharmaceuticals, be widely used in outpatient care and
generate a substantial cost to society. Therapeutic groups
used both for short- and long-term treatments were
included (long-term treatment > 6 months) with an
emphasis on long-term treatment. Pharmaceuticals were
classified as substitutable if the patent had expired and
one or more equivalent products were available. Table 1
shows the five therapeutic groups as well as the pharma-
cological substances of each therapeutic group, their sta-
tus regarding substitutability and when substances
became substitutable. In general, a pharmaceutical
becomes substitutable when generic products have been
introduced after patent expiry. Three therapeutic groups
Table 1: Pharmacological substances included in the selected therapeutic groups and their substitution status.
Therapeutic group ATC-code Substance Substitutable Substitutable since*
Long-term treatments
ACE-inhibitors C09AA Captopril Yes 1 October 2002
Enalapril Yes 1 October 2002
Lisinopril Yes 1 October 2002
Ramipril Yes 1 October 2002
Quinapril No
Cilazapril No
Fosinopril No
Trandolapril No
Selective Serotonin Reuptake Inhibitors, SSRI N06AB Fluoxetine Yes 1 October 2002
Paroxetine Yes 1 October 2002
Citalopram Yes 1 October 2002
Sertraline No
Fluvoxamine No
Escitalopram No
HMG CoA-reductase inhibitors, statins C10AA Fluvastatin Yes 5 February 2003
Simvastatin Yes 28 March 2003
Pravastatin No
Atorvastatin No
Rosuvastatin No
Short-term treatments
Nucleosides and nucleotides J05AB Aciclovir Yes 1 October 2002
Ganciclovir No
Famciclovir No
Valaciclovir No
Valganciclovir No
Both short- and long-term treatments
Proton Pump Inhibitors, PPI A10BC Omeprazole Yes 28 March 2003
Lansoprazole No
Pantoprazole No
Esomeprazole No
Rabeprazole No
* The date when the substance became substitutable according to the Swedish Medical Products Agency given for substitutable substances.BMC Health Services Research 2008, 8:50 http://www.biomedcentral.com/1472-6963/8/50
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mainly used for long-term treatment were included. These
were: 1) ACE-inhibitors (antihypertensives), 2) selective
serotonin reuptake inhibitors, SSRIs (antidepressants)
and 3) HMG CoA-reductase inhibitors, referred to as stat-
ins (cholesterol and triglyceride reducers). One group
mainly used for short-term treatment, 4) nucleosides and
nucleotides (antiviral), and one group used both for
short- and long-term treatment, 5) proton pump inhibi-
tors, PPIs (antiulcer agents), were also included. In gen-
eral, the groups comprised top-selling substances covering
both statuses of substitutability. For the two top-selling
ACE-inhibitors, enalapril and ramipril, the situation was
somewhat different. Generic versions of enalapril became
available in the beginning of 2000. However, for ramipril
there were only two alternatives, both were branded prod-
ucts produced by different premium brand companies,
available until 2004 when generics became available.
These were considered substitutable from October 2002
although there was no price competition.
Sales data for the selected therapeutic groups comprising
dispensed prescription pharmaceuticals encompassed by
the PBS were included in the study. The study period cov-
ered pharmaceuticals dispensed between 1 January 2000
and 30 June 2005. Sales data of dispensed prescribed
medicines (i.e. regular prescriptions and multidose-dis-
pensed drugs) in outpatient care for the substances in the
selected therapeutic groups were collected from the
National Corporation of Swedish Pharmacies (Apoteket
AB). Monthly sales data were collected that encompassed
Sweden in total. Data comprised volumes sold, expressed
as defined daily doses (DDD) with information on both
substance and product as well as information on age, gen-
der and place of residency of the patients collecting the
dispensed drugs. Defined daily doses were constant over
the study period. Age was divided into six categories: 0–4,
5–14, 15–44, 45–64, 65–74 and 75-years old. Due to few
observations, no separate examinations were undertaken
of the two youngest age categories.
The volumes of substitutable and non-substitutable sub-
stances were combined into two groups (denoted substi-
tutable pharmaceuticals and non-substitutable
pharmaceuticals) for comparison. Sales of non-substitut-
able packages, for example when only one company pro-
duces a certain package-size or strength, of substitutable
substances were removed from the sales of that substance.
Defined daily doses per 1000 inhabitants and day (DDD/
tid) were calculated both for total volume of the sub-
stances, each substance and specifically for each age and
gender group. Data on both total volumes of substitutable
and non-substitutable pharmaceuticals as well as each
substance were presented graphically. The sales patterns
of dispensed drugs in the different subsets were compared
with a descriptive approach, in order to investigate
whether the sales pattern changed when the reform was
implemented. The study was approved by the Ethics Com-
mittee at Göteborg University.
Results
Sales patterns of substitutable and non-substitutable drugs
A comparison of the total volumes of substitutable and
non-substitutable pharmaceuticals in the three therapeu-
tic groups mainly used for long-term treatment (ACE-
inhibitors, SSRIs and statins) showed that the volumes of
substitutable pharmaceuticals were proportionally higher
throughout the period (Figure 1). As shown in Figure 1,
the volumes of substitutable statins tripled over the study
period, whereas the volumes of non-substitutable statins
doubled before the introduction of the reform and
decreased somewhat thereafter. For the group mainly used
for short-term treatment, nucleosides and nucleotides, the
overall volume increased over the period. The sales of
non-substitutable pharmaceuticals were proportionally
higher than the sales of substitutable pharmaceuticals in
this group. Until July 2003 there was a decrease in the vol-
umes of substitutable PPIs, used both for short- and long-
term treatment, to half of the initial volume when ome-
prazole became substitutable. Thereafter the volume
increased and at the end of the study period it had almost
reached its initial level. For non-substitutable PPIs, the
pattern was the opposite.
There was an apparent change in the sales pattern for stat-
ins and PPIs during the year of implementation of generic
substitution that was not seen in the other groups. The
sales patterns for two of the selected groups, ACE-inhibi-
tors and nucleosides and nucleotides, were unaffected by
the reform.
As shown in Figure 2, sales of substances that became sub-
stitutable after the reform was introduced, constitute the
largest volumes in all groups with the exception of the
nucleosides and nucleotides. Top-selling non-substituta-
ble substances have levelled out or decreased in four out
of five groups since the reform was introduced. The sales
pattern of the ACE-inhibitors has been somewhat differ-
ent, as the two largest products are both substitutable.
There has been a proportionally larger increase in the vol-
umes of enalapril compared with ramipril since the intro-
duction of the reform.
Sales patterns of substitutable and non-substitutable drugs 
by age and gender
The volumes of dispensed prescription pharmaceuticals
varied across different age groups in the selected therapeu-
tic groups. In general the levels of DDD/tid increased as
age increased, except for nucleosides and nucleotides
where the situation was the opposite. The volumes of
SSRIs as well as nucleosides and nucleotides were higherBMC Health Services Research 2008, 8:50 http://www.biomedcentral.com/1472-6963/8/50
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Total sales volumes of non-substitutable and substitutable drugs in the included therapeutic groups Figure 1
Total sales volumes of non-substitutable and substitutable drugs in the included therapeutic groups. Volumes 
expressed as defined daily doses per 1000 inhabitants and day (DDD/1000 inhabitants and day). The two vertical reference 
lines indicate the implementation period for generic substitution (1 October 2002–30 September 2003).
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Volumes sold of each substance in the included therapeutic groups Figure 2
Volumes sold of each substance in the included therapeutic groups. Volumes sold for each substance included in the 
selected therapeutic groups, expressed as defined daily doses per 1000 inhabitants and day (DDD/1000 inhabitants and day). 
The two vertical reference lines indicate the implementation period for generic substitution (1 October 2002–30 September 
2003). An * after the substance name indicates a substitutable substance.
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among females than males, whereas the volumes of ACE-
inhibitors and statins were higher among males than
among females.
In two groups for long-term use, ACE-inhibitors and stat-
ins, there were few differences in how the sales pattern
developed for substitutable and non-substitutable drugs
between different age and gender groups (data not
shown). The sales pattern of substitutable and non-substi-
tutable SSRIs varied between different age and gender
groups (data not shown). For females aged 15–44, 45–64
and 65–74 years the volumes of non-substitutable SSRIs
more than doubled from the start of the study period until
the reform was implemented, and thereafter levelled out.
A slight increase was seen for males of corresponding age
but not as manifested as for females. Sales of substitutable
increased somewhat in these age categories after the intro-
duction of the reform.
For nucleosides and nucleotides the volumes of non-sub-
stitutable drugs were higher than the volumes of substitut-
able drugs in younger age groups (data not shown).
However, at the end of the study period volumes of sub-
stitutable nucleosides and nucleotides were at the same
level as non-substitutable nucleosides and nucleotides in
the oldest age group. Volumes of both non-substitutable
and substitutable nucleosides and nucleotides increased
in the three youngest age groups. This was seen for both
genders. For both males and females over 75 years of age,
volumes of non-substitutable nucleosides and nucle-
otides remained unchanged, whereas volumes of substi-
tutable nucleosides and nucleotides increased.
For PPIs the sales patterns of substitutable and non-sub-
stitutable drugs were similar in different age and gender
groups (data not shown). However, when volumes of
each substance were examined, the sales pattern for
esomeprazole varied. Relatively speaking, esomeprazole
was more frequent in younger people than in older age
groups. There were no differences between the genders.
Discussion
The present study showed a proportionally larger increase
in the volumes of dispensed substitutable pharmaceuti-
cals compared with non-substitutable pharmaceuticals,
since the introduction of generic substitution. Thus sales
of substitutable drugs have increased proportionally more
than non-substitutable drugs, which indicates that low-
ered prices have contributed to an increase in the prescrip-
tion of substitutable drugs. The changes were more
marked in therapeutic groups where the patents expired
during the implementation of the reform; however, this
should be interpreted with caution, as this study used a
descriptive approach. There were no differences between
short- and long-term treatments where expiry of patents
was close at hand. Differences in sales patterns were more
often observed between different age groups than
between the genders. Differences in sales patterns were
not homogeneous across age and gender and between the
selected therapeutic groups. There was a tendency that
recently introduced non-substitutable pharmaceuticals
were relatively more frequently sold in the youngest age
groups.
The increased volumes of dispensed substitutable phar-
maceuticals in the selected therapeutic groups indicated
that prescribers facilitated the implementation of the
reform, thus contributing to savings. This is in line with a
previous study, reporting that substitution was seldom
restricted by the prescriber [11]. The pronounced compe-
tition, resulting in reduced prices of many substitutable
products, might have been an important contributor to
the increased sales of these products. For example, in Feb-
ruary 2006 the price of one of the most frequently sold
packages of generic citalopram corresponded to 10–15%
of the price of original brand citalopram before the
reform. Reduced prices following the introduction of
generic substitution have also been reported from other
countries [5,6]. In Sweden, reduced prices, combined with
the ongoing process of decentralisation of budget respon-
sibility for reimbursed pharmaceuticals, might have pro-
vided incentives for the physicians to be more cost-
conscious when prescribing. This is in line with studies of
the British fundholding schemes that reported an increase
in the prescription of generic products in fundholding
practices, which contributed to lower costs per volume of
prescribed pharmaceuticals [18,19]. Other factors that
might have influenced sales patterns are recommenda-
tions from the county councils' Drug and Therapeutics
Committees, DTC, discussions on safety issues of rather
new pharmaceuticals, marketing as well as new studies on
effects and safety of pharmaceuticals. Each county council
has their own DTCs, and thus recommended drugs can
vary within the country. In general DTCs revise their
advice once a year. Many DTCs have changed their advice
to recommend products that have recently become substi-
tutable when the patent of a large product has expired.
In general the most dramatic changes are expected when
patents expire, even when there is no substitution policy.
However, the magnitude of these changes depends on a
number of factors, such as policies that enable dispensing
of generic alternatives, the prescribing habits of physi-
cians, and incentives for patients to be cost-conscious. The
marked effects seen for statins and PPIs were probably
affected by the pronounced price competition for top-sell-
ing substances where the patent had expired during
implementation of the reform. However, the design of
this study does not allow for assessment of possible differ-
ences in comparison with a situation where there is noBMC Health Services Research 2008, 8:50 http://www.biomedcentral.com/1472-6963/8/50
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generic substitution. Price differences between originator
and generic products were greater in the groups where the
patent had expired recently. This seemed to be an impor-
tant factor influencing sales patterns, as there were no dif-
ferences between short- and long-term treatments with
similar patent expiry times. There were also a larger
number of generic alternatives in these groups than in
groups where the patent had expired some years ago,
which, together with DTC recommendations, might have
contributed to the dramatic effects. For therapeutic groups
where the patent of the substitutable substances had
expired some years before the reform was introduced,
ACE-inhibitors and nucleosides and nucleotides, changes
in sales patterns related to the introduction of the reform
were not as pronounced. However, on substance level
there was a delayed increase in sales of non-substitutable
substances in both groups. Altogether, these results are in
accordance with a previous study which reported that the
proportion of performed substitutions was highest in
groups where the patent had expired close to the introduc-
tion of the reform and price differences were considerable
[11]. The potential impact of DTC recommendations can
be illustrated by the patent expiry of one of the nucleo-
sides and nucleotides. The sales of substitutable nucleo-
sides and nucleotides, i.e. aciclovir, started to increase in
2001, when the patent expired and cheaper products con-
taining aciclovir became available. Several DTCs recom-
mended the generic products which contributed to
increased volumes of aciclovir.
It was somewhat surprising that the sales pattern of the
two top-selling substitutable ACE-inhibitors (enalapril
and ramipril) was similar to that seen for substitutable
and non-substitutable drugs in other groups. Ramipril
was similar to a non-substitutable substance since there
were few substitutable products and little price competi-
tion until 2004, which was reflected by a higher price per
dose compared with enalapril, where generic products
were available when generic substitution was introduced.
Another factor that might have affected sales patterns is
the recommendations from the DTCs that varied between
the three largest county councils, as well as over time. One
recommended the use of ramipril, one recommended
enalapril, whereas the third recommended both ramipril
and enalapril.
Strengths and limitations
All groups except nucleosides and nucleotides were
among the five top-selling main drug groups during the
study period regarding volume of DDD. Nucleosides and
nucleotides were among the most widely sold anti-infec-
tive groups for short-term treatment fulfilling inclusion
criteria. Three groups: PPIs, statins and SSRIs, were among
the five groups that generated the highest expenditures
between 2003 and 2005. Expenditure has decreased since
the reform was introduced for several groups where the
major products became substitutable, e.g. ACE-inhibitors
and statins. Although the investigated groups are widely
used, it should be noted that the results are not generalis-
able to all therapeutic groups comprising substitutable
and non-substitutable pharmaceuticals. Sales patterns
depend on the prevalence and nature of the disease in
question, the characteristics of the drugs in the group, and
also on when the patent expires and which products
become substitutable.
A limitation of the study was that sales data comprising
dispensed prescription medicines were used to reflect
changes in prescribing patterns in this study. Not all pre-
scribed medication is actually purchased by patients, and
thus there is a gap between sales and prescribing data
[20,21]. On the other hand, sales data provided full cov-
erage of all dispensed prescription pharmaceuticals in
Sweden over more than five years, with more than two
years of baseline sales of the drugs before the introduction
of the reform. We have no reason to believe that failure to
purchase prescribed medication would differ with respect
to substitutable and non-substitutable drugs, since both
were equally covered by the PBS. Another limitation was
that the data did not cover drugs provided to patients in
hospitals, since these data are only registered in patient
records. However, the selected pharmaceuticals are
mainly used in outpatient care and thus data on dispensed
prescription medicines provides a reliable picture. Com-
parisons of volumes across different age and gender
groups were not adjusted for the epidemiology of the drug
use, as the study used a descriptive approach. However,
the level and distribution of volumes across age and gen-
der were in accordance with previous studies [22-25]. No
formal statistical analysis, such as time series analysis, was
undertaken in this study. The main reasons for this were
that the aim was to explore how sales patterns had devel-
oped rather than to analyse effects, and also that the data
were not suitable for time series analysis. In order to
reduce dilution, the sales of non-substitutable packages of
substitutable substances were removed, although these
constituted small volumes. Examples of non-substitutable
packages include oral suspensions, ocular ointment and
combination products. These products comprised rather
small volumes of these substances, in general below 1%.
An exception was fluvastatin, where a rather frequently
prescribed strength of depot capsule was non-substituta-
ble since no equivalent products were available.
Conclusion
Since the introduction of generic substitution, there has
been a proportionally larger increase in the volumes of
dispensed substitutable drugs compared with the volumes
of non-substitutable pharmaceuticals, indicating that the
reform has contributed to an increase in sales of lessBMC Health Services Research 2008, 8:50 http://www.biomedcentral.com/1472-6963/8/50
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expensive pharmaceuticals. This was especially pro-
nounced for therapeutic groups where one or more major
patents expired during the implementation of the reform.
However, this study cannot assess whether this differed
compared with patent expiry in a setting without generic
substitution. This thus indicates that the reduction in
prices might have affected the prescription of pharmaceu-
ticals, contributing to increased sales of substitutable
products, which in turn implies increased sales of less
expensive equivalents.
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